Genfit (GNFT) has released an update.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
GENFIT, a biopharmaceutical company focusing on severe liver diseases, has announced its upcoming Combined Shareholders Meeting scheduled for May 22, 2024. Shareholders will have access to the meeting’s documents on the company’s website and can submit their votes via the VOTACCESS platform. GENFIT, known for its extensive work in liver disease research, has a diverse pipeline with programs in various development stages.
For further insights into GNFT stock, check out TipRanks’ Stock Analysis page.
